Market Research Logo

Global Breast Cancer Monoclonal Antibodies Market 2016-2020

Global Breast Cancer Monoclonal Antibodies Market 2016-2020

About Breast Cancer mAbs

Breast cancer is characterized by the malignancy of cells in the tissues of the breast. HER-2 breast cancer is the most common type of breast cancer. The HER-2 protein, present on the surface of normal breast cells, affects the growth of the malignant cells. The uncontrolled synthesis of this protein stimulates the growth and division of malignant cells. Antibodies are the proteins produced by B-cells (in the bone marrow) in the immune system. These proteins attach themselves to antigens, which act as markers, and are then destroyed by phagocytes. B-cells produce different antibodies, which attach themselves to different sites of an antigen. mAbs are monospecific, as they are the clones of a single parent cell.

Technavio’s analysts forecast the global breast cancer monoclonal antibodies (mAbs) market to post a revenue of 13.7 billion by 2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global breast cancer monoclonal antibodies (mAbs) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sale of branded mAbs and biosimilars used to treat breast cancer.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • Amgen
  • Roche
  • Mylan
Other prominent vendors
  • Array BioPharma
  • AstraZeneca
  • Biocad
  • Boehringer Ingelheim
  • Bristol-Myers Squibb
  • Celldex Therapeutics
  • Celltrion
  • Chugai Pharmaceutical
  • Daiichi Sankyo
  • DARA Biosciences
  • Eddingpharm
  • Eisai
  • Galena Biopharma
  • GlaxoSmithKline
  • Halozyme Therapeutics
  • Hospira
  • ImmunoGen
  • Immunomedics
  • MacroGenics
  • Merck
  • Novartis
  • Oncothyreon
  • Pfizer
  • ProStrakan
  • Puma Biotechnology
  • Seattle Genetics
  • Sun Pharmaceutical Industries
  • Synta Pharmaceuticals
  • Teva Pharmaceuticals
Market driver
  • Reimbursement benefits for breast cancer mAbs
  • For a full, detailed list, view our report
Market challenge
  • Absence of adequate diagnosis and screening procedures for early detection
  • For a full, detailed list, view our report
Market trend
  • Emergence of targeted and combination therapies for breast cancer
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Breast Cancer Monoclonal Antibodies (mAbs) Market 2016-2020

Technavio recognizes the following companies as the key players in the global breast cancer monoclonal antibodies (mAbs) market: Roche, Amgen, and Mylan.

Other Prominent Vendors in the market are: Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, and Teva Pharmaceuticals.

Commenting on the report, an analyst from Technavio’s team said: “Huge funds are required for a company to enter the global breast cancer mAbs market and invest in the R&D and manufacturing processes related to the same. Vendors have identified mAb products as a significant long-term growth opportunity. The pharmaceutical industry is a research-intensive industry backed by developments in technology. The vendors in this market are allocating huge R&D budgets to enable the introduction of a broad portfolio of mAbs. This would help increase the market penetration of the vendors in the global market to a great extent. Thus, the huge investment in the R&D of mAbs is another trend witnessed by the global breast cancer mAbs market, influencing market growth.”

According to the report, exposure to risk factors will be a key driver for market growth. Exposure to risk factors for breast cancer and the decrease in practices that reduce this risk are expected to increase the incidence of breast cancer. The disease is associated with modifiable risk factors such as physical inactivity, alcohol consumption, obesity, and weight gain. For instance, the use of hormonal therapy after menopause and the use of contraceptives are potential risks for developing breast cancer. Oral contraceptives and postmenopausal estrogen-progestogen hormone replacement therapy increase the risk of the developing the disease because they contain synthetic sex hormones. Overweight postmenopausal women have elevated estrogen levels because they have more estrogen-producing fatty tissue. These levels increase the likelihood of developing the disease. Physical activity helps lower estrogen levels, and thus negates the risk factors. Breastfeeding is also known to protect women against breast cancer.

Further, the report states that the number of patients available for clinical studies is less, making it difficult to generate significant comparative data. This is a major challenge in conducting clinical studies and for the market. The participation of sites across multiple geographies is required, but only very few patients are enrolled at each site. This may lead to delays in the recruitment process, which can add to the cost and uncertainty of the program. Pharmaceutical companies developing mAbs conduct clinical trials on a limited patient population. This requires efforts to mitigate the higher risk of uncertainty associated with the use of these drugs and accelerates approval procedures. The US FDA mandates manufacturers to satisfy Risk Evaluation and Mitigation Strategy (REMS) programs that include elements to ensure safe use before and after approval. The assessment of safety labels during clinical trials becomes difficult because of the limited availability of premarket data for the evaluation of mAbs and the smaller patient population.

Companies Mentioned

Roche, Amgen, Mylan, Actavis, Array BioPharma, AstraZeneca, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, Celldex Therapeutics, Celltrion, Chugai Pharmaceutical, Daiichi Sankyo, DARA Biosciences, Eddingpharm, Eisai, Galena Biopharma, GlaxoSmithKline, Halozyme Therapeutics, Hospira, ImmunoGen, Immunomedics, MacroGenics, Merck, Novartis, Oncothyreon, Pfizer, ProStrakan, Puma Biotechnology, Seattle Genetics, Sun Pharmaceutical Industriesf, Synta Pharmaceuticals, Teva Pharmaceuticals.

  • Executive summary
    • Highlights
  • Scope of the report
    • Market overview
    • Assumptions
    • Top-vendor offerings
      • Table Product offerings
  • Market research methodology
    • Research methodology
    • Economic indicators
  • Introduction
    • Key market highlights
      • Table Global breast cancer mAbs market snapshot
      • Table Key buying criteria for breast cancer mAbs 2015
      • Table Impact of key customer segments on market 2015
  • Breast cancer: Overview
    • Understanding the disease
    • Treatment regimen for breast cancer
      • Table Breast cancer stages based on tumor size and extent of metastasis
      • Table Classification of breast cancer based on genetic make-up of tumor cells
      • Table Treatment regimen for breast cancer
    • Overview of mAbs
      • Table Comparison of small molecules and mAbs
      • Table Preparation of mAbs
      • Table Global breast cancer mAbs market: Key metrics analysis snapshot
  • Pipeline portfolio
    • Table Global breast cancer mAbs market: Pipeline snapshot 2015
    • Table Pipeline portfolio: Global breast cancer mAbs market 2015
    • Table Developmental history of trastuzumab biosimilars in various countries
  • Market landscape
    • Market overview
      • Table Global breast cancer mAbs market snapshot: Developed and emerging markets 2015
      • Table Global breast cancer mAbs market 2015-2020 ($ billions)
      • Table Factors influencing global breast cancer mAbs market 2015
      • Table Timeline for development of breast cancer mAbs
      • Table Impact of drivers and challenges of global breast cancer mAbs market
    • Five forces analysis
      • Table Five forces analysis
  • Market segmentation by type of mAbs
    • Naked mAbs
      • Table Approved naked mAbs by US FDA and EU
    • Conjugated mAbs
      • Table Global breast cancer mAbs market segmentation by type of molecule 2015
  • Market segmentation by end-user
    • Hospitals
    • Retail pharmacies
      • Table Global breast cancer mAbs market segmentation by end-user 2015
  • Geographical segmentation
    • Global breast cancer mAbs market by geographical segmentation 2015-2020
      • Table Global breast cancer mAbs market: Geographical outlook 2015-2020
      • Table Global breast cancer mAbs market: Geographical outlook 2015
      • Table Revenue/growth outlook in different countries/regions 2015
      • Table Global breast cancer mAbs market segmentation by region: Market growth lifecycle analysis 2015
    • Breast cancer mAbs market in Americas
      • Table Opportunity analysis of breast cancer mAbs market in Americas
      • Table Breast cancer mAbs market in Americas 2015-2020 ($ billions)
      • Table Breast cancer mAbs market in Americas by country 2015
    • Breast cancer mAbs market in EMEA
      • Table Opportunity analysis of breast cancer mAbs market in EMEA
      • Table Breast cancer mAbs market in EMEA 2015-2020 ($ billions)
    • Breast cancer mAbs market in APAC
      • Table Opportunity analysis of breast cancer mAbs market in APAC
      • Table Number of individuals treated with Herceptin through patient assistance programs in China 2011-2014
      • Table Breast cancer mAbs market in APAC 2015-2020 ($ billions)
      • Table Global breast cancer mAbs market revenue by geography 2015-2020 ($ billions)
  • Market drivers
    • Reimbursement benefits for breast cancer mAbs
    • Increase in demand for breast cancer ADCs
    • Huge market potential for breast cancer mAbs owing to product approvals
    • Exposure to risk factors
  • Impact of drivers
    • Table Impact of drivers
  • Market challenges
    • Absence of adequate diagnosis and screening procedures for early detection
      • Table Five-year survival rate by stage of diagnosis
    • High manufacturing costs coupled with stringent regulations
    • Threat from chemotherapy and off-label drugs
    • Difficulties in patient recruitment for conducting clinical trials
  • Impact of drivers and challenges
    • Table Impact of drivers and challenges
  • Market trends
    • Table Global breast cancer mAbs market: Impact assessment of key trends
    • Emergence of targeted and combination therapies for breast cancer
    • Growing focus of vendors on untapped markets
    • Emergence of biosimilars
    • Outsourcing of biosimilar manufacturing activities
    • Need for high investment in R&D
  • Vendor landscape
    • Competitive scenario
      • Table Competitive assessment of vendors
      • Table Key vendors: Geographical presence 2015
    • Key news
    • Roche
      • Table Roche: YoY growth and revenue generated from net product sales of Avastin 2013-2015 ($ billions)
      • Table Roche: Geographical segmentation of Avastin by revenue 2015
      • Table Roche: YoY growth and revenue generated from net product sales of Herceptin 2013-2015 ($ billions)
      • Table Roche: Geographical segmentation of Herceptin 2015
      • Table Roche: YoY growth and revenue generated from net product sales of Perjeta 2013-2015 ($ billions)
      • Table Roche: Geographical segmentation of Perjeta 2015
      • Table Roche: Revenue generated from net product sales of Kadcyla 2013-2015 ($ millions)
      • Table Roche: Geographical segmentation of Kadcyla 2015
      • Table Roche: Metrics analysis
    • Amgen
      • Table Amgen: YoY growth and revenue generated from net product sales of Xgeva 2013-2015 ($ billions)
      • Table Amgen: Geographical segmentation of Xgeva 2015
      • Table Amgen: Metrics analysis
    • Mylan
      • Table Mylan: Business segmentation by revenue 2015
      • Table Mylan: Geographical segmentation by revenue 2015 (generics segment)
      • Table Mylan: Metrics analysis
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report